Cargando…

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer

BACKGROUND: Although it has been suggested that a high level of thymidylate synthase (TYMS) gene expression in malignant tumors is related to reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an association has been demonstrated in routine clinical samples from patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chamizo, Cristina, Zazo, Sandra, Dómine, Manuel, Cristóbal, Ion, García-Foncillas, Jesús, Rojo, Federico, Madoz-Gúrpide, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623912/ https://www.ncbi.nlm.nih.gov/pubmed/26502926 http://dx.doi.org/10.1186/s12890-015-0132-x

Ejemplares similares

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

Comment on ‘MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells’
por: Cristóbal, Ion, et al.
Publicado: (2017)

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer
por: Rubio, Jaime, et al.
Publicado: (2021)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
por: González-Alonso, Paula, et al.
Publicado: (2015)

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
por: Bukhari, Ali A., et al.
Publicado: (2013)

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2019)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

Functional and Clinical Impact of CircRNAs in Oral Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells
por: Santos, Andrea, et al.
Publicado: (2023)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2020)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer
por: Cristóbal, Ion, et al.
Publicado: (2015)

Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells
por: Buqué, Aitziber, et al.
Publicado: (2013)

MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
por: Kawabata, Shigeru, et al.
Publicado: (2014)

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
por: Wang, Xia, et al.
Publicado: (2013)

The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
por: Wang, Lei, et al.
Publicado: (2014)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase
por: Kuo, Wei-Ting, et al.
Publicado: (2017)

Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer
por: Li, Tao, et al.
Publicado: (2020)

Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
por: HU, QIONG, et al.
Publicado: (2012)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)

Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging
por: Chen, Xiao, et al.
Publicado: (2016)

The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase
por: Ding, Xinyuan, et al.
Publicado: (2020)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2021)

Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells'
por: Cristobal, I, et al.
Publicado: (2014)

Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
por: Chen, Chung-Yu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q4ubpdhs4pkfd9kopusvinj1ok